Ken Griffin Editas Medicine, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$3.39 - $5.96 $211,536 - $371,904	-62,400 Reduced 48.11%	67,300 $229,000
Q2 2024 Aug 14, 2024	BUY	$4.67 - $7.28 $307,753 - $479,752	65,900 Added 103.29%	129,700 $605,000
Q1 2024 May 15, 2024	SELL	$7.03 - $11.07 $182,780 - $287,820	-26,000 Reduced 28.95%	63,800 $473,000
Q4 2023 Feb 14, 2024	SELL	$6.25 - $11.11 $269,375 - $478,841	-43,100 Reduced 32.43%	89,800 $909,000
Q3 2023 Nov 14, 2023	SELL	$6.92 - $9.31 $305,172 - $410,571	-44,100 Reduced 24.92%	132,900 $1.04 Million
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $198,432 - $357,864	31,200 Added 21.4%	177,000 $1.46 Million
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $234,802 - $385,102	-33,400 Reduced 18.64%	145,800 $1.06 Million
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $173,056 - $274,768	-20,800 Reduced 10.4%	179,200 $1.59 Million
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $666,368 - $1.06 Million	-54,800 Reduced 21.51%	200,000 $2.45 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $82.5M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.